Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed))

MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC


NEW YORK, April 16, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. The safety trial has commenced on time and as scheduled, even during the COVID-19 pandemic. 18-MC is a proprietary, orally active, non-hallucinogenic molecule based on the psychedelic ibogaine.  

MindMed is developing 18-MC as a potential treatment for ...

Continue Reading →